Both Anaconda and The Great Flood serve as reflections of their respective genres, showcasing the absurdity of comedy and the chaos of disaster narratives. Anaconda delights with its humorous take on ...

Shanda Group has entered a period of renewed visibility, with a series of incubated ventures coming to light over the past several months. At the center of this momentum is its founder, Tianqiao Chen, ...

Recursion Pharmaceuticals, Inc. is upgraded to Buy, supported by promising REC-4881 data and strong institutional backing. REC-4881's Phase 1b/2 data in FAP show a 43% median polyp reduction, ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...